Cardiovascular Outcomes, and Mortality in Danish Patients With Type 2 Diabetes Who Initiate Empagliflozin Versus Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA): A Danish Nationwide Comparative Effectiveness Study [EMPLACEtm]
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 26,774
- 试验地点
- 1
- 主要终点
- Incidence Rate of Expanded Major Adverse Cardiovascular Event (MACE) Composite Outcome - OT Analysis
研究概览
简要总结
The primary research question is to evaluate whether, among patients with type 2 diabetes mellitus (T2D), initiation of empagliflozin changes the adjusted incidence of outcomes compared with initiation of Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The empagliflozin-exposed population must also meet the following criteria:
- •Have at least one prescription for empagliflozin or fixed-dose combination of empagliflozin with another drug, with or without treatment with another glucose-lowering drug
- •Have no prescription/dispensing of SGLT2 inhibitors (including empagliflozin) alone or in fixed-dose combination prior to the index date
- •Have no prescription/dispensing of a GLP-1 receptor agonist alone or in fixed dose combination prior to the index date
- •The population exposed to GLP1-RA must meet the following criteria:
- •Have at least one prescription for GLP1-RA or a fixed-dose combination of GLP1-RA with another drug, with or without treatment with another glucose-lowering drug.
- •Have no prescription/dispensing of a GLP-1 receptor agonist alone or in fixed dose combination prior to the index date
- •Have no prescription/dispensing of SGLT2 inhibitors (including empagliflozin) alone or in fixed-dose combination prior to the index date
排除标准
- •Patients with type 1 diabetes T1D before the index date will not be included in the study.
- •Exclusion criteria by outcome of interest: Different exclusion criteria will be applied to generate sets of cohorts for the analysis of the different outcomes of interest.
- •In one main analysis, we will assess co-primary and secondary outcomes among all patients, regardless of a history of previous outcome events being present or not. In other words, we will allow a previous history of CVD events. We will adjust for the history of these events in the regression model rather than excluding patients with previous events (e.g. assess outcome rates of myocardial infarction in empagliflozine and liraglutide initiators while adjusting for previous history of myocardial infarction, unstable angina, or coronary revascularization).
- •In another main analysis of outcomes, we will exclude patients who had a specific outcome previously.
- •For example in the analysis of the primary heart failure outcome (heart failure admission or loop-diuretics), patients will not be included if a diagnosis of heart failure is recorded any time before or at the index date, or if a prescription for loop-diuretics has been filled within 12 months before or at the index date. For the secondary outcome of acute hospital admission with heart failure, we will include also patients with previous prescription for loop-diuretics, but exclude those with previous heart failure admission.
- •For analysis of stroke, patients will not be included if a diagnosis of stroke is recorded any time before or at the index date.
- •For analysis of myocardial infarction, unstable angina, or coronary revascularization, patients will not be included if any of these 3 major atherosclerotic cardiovascular events are recorded any time before or at the index date.
- •In additional analyses, other criteria will apply (To be discussed, RWT). Thus, an additional analysis will include also patients with previous outcome events, and adjust for the history of these events in the regression model rather than excluding them (e.g. assess outcome rates of myocardial infarction in empagliflozine and liraglutide initiators while adjusting for previous history of myocardial infarction, unstable angina, or coronary revascularization).
研究组 & 干预措施
Patients with type 2 diabetes
干预措施: Empagliflozin (Drug)
Patients with type 2 diabetes
干预措施: Liraglutide (Drug)
结局指标
主要结局
Incidence Rate of Expanded Major Adverse Cardiovascular Event (MACE) Composite Outcome - OT Analysis
时间窗: From first initiation of empagliflozin or liraglutide until end of follow-up, up to 6 years.
Composite outcome includes: All-cause death, acute admission with non-fatal (within 30 days) stroke, with non-fatal (within 30 days) myocardial infarction (MI), admission with unstable angina, coronary revascularization, or acute admission with non-fatal heart failure (HF). The results from on-treatment (OT) analysis are reported. For the OT analyses, treatment duration was based on the estimated number of days covered by each filled prescription, calculated as the number of drug packages times the numerical volume of a package. A grace period of 30 days were added. In the OT analysis, participants were censored from further follow-up at either treatment cessation, initiation of an alternative drug in the study drug class and initiation of a drug from the comparator study drug class.
Incidence Rate of Expanded Major Adverse Cardiovascular Event (MACE) Composite Outcome - ITT Analysis
时间窗: From first initiation of empagliflozin or liraglutide until end of follow-up, up to 6 years.
Composite outcome includes: All-cause death, acute admission with non-fatal (within 30 days) stroke, with non-fatal (within 30 days) myocardial infarction (MI), admission with unstable angina, coronary revascularization, or acute admission with non-fatal heart failure (HF). The results from intention-to-treat (ITT) analysis are reported. For the ITT analyses, participants were defined as exposed from the start of treatment throughout follow-up, analogous to an ITT design in a interventional trial. Follow-up was not censored if glucose-lowering drugs other than the index drugs were prescribed in addition to empagliflozin or GLP-1RA after the index date.
次要结局
- Incidence Rate of All-cause Hospitalization or Death - OT Analysis(From first initiation of empagliflozin or liraglutide until end of follow-up, up to 6 years.)
- Incidence Rate of Heart Failure (HF) Hospitalization or All-cause Death - ITT Analysis(From first initiation of empagliflozin or liraglutide until end of follow-up, up to 6 years.)
- Incidence Rate of First Hospitalized Heart Failure (HHF) or Initiation of Community Prescription Drug Therapy With Loop Diuretics - ITT Analysis(From first initiation of empagliflozin or liraglutide until end of follow-up, up to 6 years.)
- Incidence Rate of All-cause Hospitalization or Death - ITT Analysis(From first initiation of empagliflozin or liraglutide until end of follow-up, up to 6 years.)
- Incidence Rate of Heart Failure (HF) Hospitalization or All-cause Death - OT Analysis(From first initiation of empagliflozin or liraglutide until end of follow-up, up to 6 years.)
- Incidence Rate of First Hospitalized Heart Failure (HHF) or Initiation of Community Prescription Drug Therapy With Loop Diuretics - OT Analysis(From first initiation of empagliflozin or liraglutide until end of follow-up, up to 6 years.)
- Incidence Rate of All Cause Hospitalization - OT Analysis(From first initiation of empagliflozin or liraglutide until end of follow-up, up to 6 years.)
- Incidence Rate of All-cause Death - OT Analysis(From first initiation of empagliflozin or liraglutide until end of follow-up, up to 6 years.)
- Incidence Rate of All Cause Hospitalization - ITT Analysis(From first initiation of empagliflozin or liraglutide until end of follow-up, up to 6 years.)
- Incidence Rate of All-cause Death - ITT Analysis(From first initiation of empagliflozin or liraglutide until end of follow-up, up to 6 years.)
- Incidence Rate of Hospitalization for Heart Failure (HF) - OT Analysis(From first initiation of empagliflozin or liraglutide until end of follow-up, up to 6 years.)
- Incidence Rate of Hospitalization for Heart Failure (HF) - ITT Analysis(From first initiation of empagliflozin or liraglutide until end of follow-up, up to 6 years.)